AI-generated summary
The authors conducted a systematic review and meta-analysis of 14 randomized controlled trials with 527 patients treated for melasma. They report that adding ablative fractional laser to a drug improved the melasma area and severity index and physician global assessment compared with the drug alone, while patient self-assessment did not differ significantly. Common adverse events were transient and mild.
- Participants
- 527
- Studies included
- 14
- Who or what was studied
- Patients with melasma, a common acquired skin pigmentation disorder
- Limits stated in the abstract
- The abstract does not describe the risk of bias or certainty of evidence, and the patient self-assessment result was not statistically significant.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Laser, Systematic review, Meta-analysis, Melanin. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.